Aurinia Pharmaceuticals (AUPH) Misses Q1 EPS by 26c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q1 EPS of ($0.40), $0.26 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• JPMorgan Downgrades HCL Technologies (HCLT:IN) to Underweight
• BMO Capital Upgrades CES Energy Solutions Corp. (CEU:CN) (CESDF) to Outperform